12 May, 2014 by The TZ Newswire Staff Comments Off on Opening Bell: 05.12.14
Opening Bell: 05.12.14
12 May, 2014 by The TZ Newswire Staff Comments Off on Will Panera 2.0 Be Better Than Panera 1.0?
Will Panera 2.0 Be Better Than Panera 1.0?
Panera’s move to Panera 2.0 could just be the trick to get same-store sales moving in the right direction and allow the chain to better compete with Chipotle Mexican Grill.
12 May, 2014 by The TZ Newswire Staff Comments Off on Amy Hoak’s Home Economics: Why millennials are hurting the real estate recovery
Amy Hoak’s Home Economics: Why millennials are hurting the real estate recovery
In today’s economy, many young adults can’t manage to buy a home—and their absence is holding back the real estate rebound.
12 May, 2014 by The TZ Newswire Staff Comments Off on Caregiving is a company problem
Caregiving is a company problem
More workers are caring for adult relatives than they are caring for children.
12 May, 2014 by The TZ Newswire Staff Comments Off on Europe Markets: European stocks gain as Rio Tinto, miners are upgraded
Europe Markets: European stocks gain as Rio Tinto, miners are upgraded
European stocks rise Monday, with mining shares advancing after an upgrade of the sector.
read more
12 May, 2014 by The TZ Newswire Staff Comments Off on Does Japan’s current account spell danger for the yen?
Does Japan’s current account spell danger for the yen?
Japan ran the smallest current account surplus on record in the 2013-14 fiscal year which could spell danger for the yen.
12 May, 2014 by The TZ Newswire Staff Comments Off on Pfizer presses AstraZeneca case as CEO faces UK grilling
Pfizer presses AstraZeneca case as CEO faces UK grilling
U.S. drugmaker Pfizer pressed the scientific case for its controversial plan to acquire AstraZeneca on Monday as its chief executive prepared for a grilling from British lawmakers. In the latest phase of Pfizer’s campaign to counter critics of its proposed $106 billion deal, research head Mikael Dolsten said he had been through five different mergers and acquisitions and denied such big transactions disrupted drug research.